On Wednesday, February 6th, FDA issued a letter to health care providers to increase the awareness of an association between all breast implants and Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL). Reports received by the FDA indicate that patients with breast implants have a higher risk of developing the disease within the scar capsule adjacent to the implant. As of the latest medical device reports (MDRs), the Agency believes that 457 cases and nine deaths were due to BIA-ALCL. In its letter, FDA specifically calls out health care providers, asking them to report all confirmed cases of BIA-ALCL in patients with breast implants as well as rates they have experienced during practice to the FDA.
In 2011, FDA was the first public health agency to identify and communicate a possible association between breast implants and the development of anaplastic large cell lymphoma (ALCL). BIA-ALCL is a type of Anaplastic Large Cell Lymphoma that can develop following breast implants. This rare blood cancer is a type of non-Hodgkin’s lymphoma, or cancer of the cells of the immune system, and is not considered breast cancer. It can occur in many different parts of the body, including the lymph nodes and skin, in cis- and trans-gender women and men. It has been reported that half of the reported cases were diagnosed within seven to eight years.
At the time of discovery, very little information was provided about the disease, but over time, the FDA has strengthened its understanding. Today, data displays that BIA-ALCL occurs more frequently following the implementation of breast implants with textured rather than smooth surfaces. According to FDA, “the type of implant fill does not appear to be a risk factor for BIA-ALCL, but this has not been evaluated in a large, well-designed, epidemiologic study. To date, there has not been sufficient data to determine whether ALCL may be found more or less frequently in individuals with silicone-filled breast implants compared to individuals with saline-filled breast implants.”
As of September 2018, the Agency had received a total of 660 BIA-ALCL related MDRs. The FDA reviewed the reports to remove duplicate reports and “to control for MDRs in which a BIA-ALCL diagnosis was confirmed by: a physician, positive pathology/cytology test results, or positive for biomarker CD30 and negative for biomarker ALK.” After the analysis, the data reflected 457 unique MDRs for BIA-ALCL and nine deaths which may be attributed to BIA-ALCL. FDA reports that “at the time of diagnosis, patients may have their original breast implants, or they may have had one or more replacements.” The agency also reports that the number is not definite to the entire span of cases in the United States.
The MDRs do not provide a patient’s history of breast implants, the reports only provide general information about the implant at the time of diagnosis. Due to the limited number of cases, the FDA emphasized the need for more information to better characterize ALCL in individuals with breast implants. The Agency emphasizes that MDRs are only valuable depending on the accuracy of data, and in the future, more data may be gathered to better understand the disease.
The Agency has developed an ongoing plan to better collect and evaluate ALCL information. FDA will:
Since 2016, there has been several major advancements in the description of the disease and treatment recommendations, including:
The FDA provides several recommendations for health care providers, including the following:
February 22, 2019
On Thursday, May 26th, FDA announced the approval of Probuphine® , a buprenorphine implant for the treatment of opioid dependence. The implant is the first device of its kind, and “is designed to...
February 22, 2019
What are Breakthrough Therapy Designation and PRIority MEdicines (PRIME) Applications? The advancement of modern medicine, and the accessibility of researched and regulated medication, has greatly...
February 22, 2019
This technical specifications document is to assist interested parties in electronically submitting individual case safety reports (ICSRs) (and ICSR attachments) to the Center for Drug Evaluation and...